ImmunityBio Inc

Subsequent Events

BLA Approval

On April 22, 2024, the FDA approved our product, ANKTIVA with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.

In April 2024, we filed a shelf registration statement and associated prospectus that increased the amount available under the ATM to $300.8 million.

Stock Purchase Option Exercise

Pursuant to the SPOA, in April 2024 Oberland exercised its option to purchase 858,990 shares of our common stock at an exercise price of $5.8208 per share generating proceeds of approximately $5.0 million. Following such exercise, approximately $5.0 million remains available for future exercise under the SPOA.

Warrant Exercises

Subsequent to March 31, 2024 through the date of this Quarterly Report, institutional holders exercised a total of 13,217,843 warrants pursuant to the February and July 2023 Warrant agreements at an exercise price of $3.2946 per share resulting in the issuance of 13,217,843 shares of the company’s common stock for proceeds totaling $43.5 million. As of May 9, 2024, a total of 11,139,420 warrants remain outstanding under the February and July 2023 Warrant agreements.